MX2009003972A - Compuesto de indol. - Google Patents

Compuesto de indol.

Info

Publication number
MX2009003972A
MX2009003972A MX2009003972A MX2009003972A MX2009003972A MX 2009003972 A MX2009003972 A MX 2009003972A MX 2009003972 A MX2009003972 A MX 2009003972A MX 2009003972 A MX2009003972 A MX 2009003972A MX 2009003972 A MX2009003972 A MX 2009003972A
Authority
MX
Mexico
Prior art keywords
indole compound
present
glucokinase activator
agent
prodrug
Prior art date
Application number
MX2009003972A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Osamu Ujikawa
Masahiro Itoh
Kazuko Aoki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39010108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009003972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2009003972A publication Critical patent/MX2009003972A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

El propósito de la presente invención es proporcionar un activador de glucocinasa útil como un agente farmacéutico tal como un agente para la profilaxis o tratamiento de diabetes, obesidad y similar. La presente invención proporciona un activador de glucocinasa que contiene un compuesto representado por la fórmula (I): en donde R1 es un átomo de hidrógeno o un átomo de halógeno; R2 es un grupo representado en donde cada símbolo se define en la especificación, o su sal o su profármaco.
MX2009003972A 2006-10-19 2007-10-18 Compuesto de indol. MX2009003972A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006285551 2006-10-19
PCT/JP2007/070772 WO2008050821A1 (en) 2006-10-19 2007-10-18 Indole compound

Publications (1)

Publication Number Publication Date
MX2009003972A true MX2009003972A (es) 2009-04-27

Family

ID=39010108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003972A MX2009003972A (es) 2006-10-19 2007-10-18 Compuesto de indol.

Country Status (26)

Country Link
US (4) US7652133B2 (es)
EP (2) EP2074119A1 (es)
JP (1) JP5260507B2 (es)
KR (1) KR101444486B1 (es)
CN (1) CN101573357B (es)
AU (1) AU2007310064B2 (es)
BR (1) BRPI0717722A2 (es)
CA (1) CA2666973C (es)
CL (1) CL2008001017A1 (es)
CR (1) CR10748A (es)
EC (1) ECSP099330A (es)
GE (1) GEP20115241B (es)
IL (1) IL198154A (es)
MA (1) MA30890B1 (es)
ME (1) MEP11809A (es)
MX (1) MX2009003972A (es)
MY (1) MY158052A (es)
NO (1) NO20091948L (es)
NZ (1) NZ576570A (es)
PE (1) PE20090884A1 (es)
RU (1) RU2454415C9 (es)
TN (1) TN2009000129A1 (es)
TW (1) TWI460176B (es)
UA (1) UA97257C2 (es)
WO (1) WO2008050821A1 (es)
ZA (1) ZA200902585B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101511074B1 (ko) * 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Ｍｃｌ-1 억제제
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8436038B2 (en) * 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
EP2220081A4 (en) * 2007-12-20 2011-08-24 Lg Life Sciences Ltd GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES
KR101098583B1 (ko) * 2008-01-04 2011-12-26 주식회사 엘지생명과학 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2720686A1 (en) 2008-04-10 2009-10-15 Takeda Pharmaceutical Company Limited Fused ring compounds and use thereof
US8349886B2 (en) 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US8288559B2 (en) * 2008-08-18 2012-10-16 Promega Corporation Luminogenic compounds and methods to detect cytochrome P450 3A enzymes
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
WO2010117085A1 (en) * 2009-04-09 2010-10-14 Banyu Pharmaceutical Co.,Ltd. Aryl indole derivatives
EP2440541A1 (en) 2009-06-09 2012-04-18 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
TW201106991A (en) 2009-07-28 2011-03-01 Takeda Pharmaceutical Tablets
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
GEP20146178B (en) 2010-04-27 2014-10-10 Takeda Pharmaceuticals Co Bicyclic compound derivatives and their usage as acc inhibitors
EA022094B1 (ru) 2010-06-16 2015-10-30 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма амидного соединения
WO2011159781A2 (en) * 2010-06-17 2011-12-22 Senomyx, Inc. Bitter taste modulators
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US20130184272A1 (en) 2010-09-17 2013-07-18 Takeda Pharmaceutical Company Limited Diabetes therapeutic agent
TW201242951A (en) 2010-11-30 2012-11-01 Takeda Pharmaceutical Bicyclic compound
SG192645A1 (en) 2011-02-17 2013-09-30 Takeda Pharmaceutical Production method of optically active dihydrobenzofuran derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013057944A1 (ja) * 2011-10-19 2013-04-25 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
CN103998432A (zh) 2011-10-24 2014-08-20 武田药品工业株式会社 双环化合物
US9365540B2 (en) 2012-01-12 2016-06-14 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as MCH receptor antagonists
WO2013122029A1 (ja) 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
JP6095580B2 (ja) 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
CA2864068A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
WO2013125732A1 (en) 2012-02-24 2013-08-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
CN104350040B (zh) 2012-03-29 2016-06-01 武田药品工业株式会社 芳环化合物
US20150087628A1 (en) * 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
JPWO2013168760A1 (ja) 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
EP2848621A4 (en) 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC CYCLIC COMPOUND
JP6122879B2 (ja) 2012-06-05 2017-04-26 武田薬品工業株式会社 固形製剤
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
EP2970331B1 (en) 2013-03-14 2017-05-17 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
UY35650A (es) 2013-07-09 2015-02-27 Takeda Pharmaceutical Compuesto heterocíclico
HUE039259T2 (hu) 2013-08-09 2018-12-28 Takeda Pharmaceuticals Co Aromás vegyület
KR102001431B1 (ko) * 2013-08-22 2019-07-18 주식회사 엘지화학 세포괴사 저해제로서의 인돌아미드 화합물
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
WO2018181847A1 (ja) 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
CA3094820A1 (en) 2018-03-23 2019-09-26 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors
AR116019A1 (es) 2018-08-27 2021-03-25 Scohia Pharma Inc Derivados de guanidinobenzoilo como inhibidores de enteropeptidasa
US20220016215A1 (en) 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
US20220135638A1 (en) 2018-09-24 2022-05-05 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
CN109250963B (zh) * 2018-09-29 2021-07-16 福建省昊立建设工程有限公司 一种复合增韧混凝土及其制备方法
JP2023524603A (ja) 2020-03-25 2023-06-12 武田薬品工業株式会社 Ｇｉｆ受容体アゴニストペプチド化合物及びその使用
TW202202516A (zh) 2020-03-25 2022-01-16 日商武田藥品工業股份有限公司 Ｇｉｐ受體促效劑肽化合物之ｑｄ給藥及其用途
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
TW202313666A (zh) 2021-05-13 2023-04-01 美商卡默療法股份有限公司 G-蛋白偶聯受體之調節劑
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656610B1 (fr) 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
KR0174752B1 (ko) * 1993-09-10 1999-02-01 나이토 하루오 이환식 헤테로환 함유 술폰아미드 유도체 및 그 제조방법
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
IL137719A0 (en) * 1998-02-25 2001-10-31 Genetics Inst Inhibitors of phospholipase enzymes
JP4007743B2 (ja) 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
GB0003636D0 (en) * 2000-02-16 2000-04-05 Smithkline Beecham Plc Novel compounds
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
DK1549638T3 (da) * 2002-10-03 2008-01-21 Hoffmann La Roche Indol-3-carboxamider som glucokinase (GK) aktivatorer
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
AU2006295645B2 (en) 2005-09-30 2011-09-29 Msd K.K. 2-heteroaryl-substituted indole derivative
US7776864B2 (en) 2007-08-14 2010-08-17 Bayer Schering Pharma Ag Fused bicyclic pyrimidines
CN101835776A (zh) 2007-08-14 2010-09-15 拜耳先灵医药股份有限公司 用于癌症治疗的稠合的咪唑
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
MX2010004177A (es) 2007-10-18 2010-05-03 Janssen Pharmaceutica Nv 1,2,4-triazoles trisustituidos.

Also Published As

Publication number Publication date
BRPI0717722A2 (pt) 2013-10-29
UA97257C2 (en) 2012-01-25
CL2008001017A1 (es) 2009-04-24
ME00681B (me) 2011-12-20
NO20091948L (no) 2009-07-13
CA2666973A1 (en) 2008-05-02
KR20090068292A (ko) 2009-06-25
CA2666973C (en) 2015-03-31
AU2007310064B2 (en) 2013-03-28
RU2454415C2 (ru) 2012-06-27
IL198154A0 (en) 2009-12-24
MA30890B1 (fr) 2009-11-02
IL198154A (en) 2014-08-31
MEP11809A (en) 2011-12-20
US7718798B2 (en) 2010-05-18
CN101573357A (zh) 2009-11-04
EP2508524A3 (en) 2012-10-24
WO2008050821A1 (en) 2008-05-02
RU2009118602A (ru) 2010-11-27
TWI460176B (zh) 2014-11-11
MY158052A (en) 2016-08-30
AU2007310064A2 (en) 2009-06-04
RU2454415C9 (ru) 2013-02-27
US20100144702A1 (en) 2010-06-10
US7652133B2 (en) 2010-01-26
US7777047B2 (en) 2010-08-17
ECSP099330A (es) 2009-06-30
EP2074119A1 (en) 2009-07-01
PE20090884A1 (es) 2009-08-05
US20080096877A1 (en) 2008-04-24
AU2007310064A1 (en) 2008-05-02
US20100137610A1 (en) 2010-06-03
TW200825071A (en) 2008-06-16
US8410087B2 (en) 2013-04-02
CR10748A (es) 2009-05-20
EP2508524A2 (en) 2012-10-10
CN101573357B (zh) 2013-01-23
TN2009000129A1 (en) 2010-10-18
ZA200902585B (en) 2010-09-29
GEP20115241B (en) 2011-06-10
NZ576570A (en) 2010-11-26
US20090286975A1 (en) 2009-11-19
KR101444486B1 (ko) 2014-09-24
JP2010506825A (ja) 2010-03-04
JP5260507B2 (ja) 2013-08-14

Similar Documents

Publication Publication Date Title
TN2009000129A1 (en) Indole compound
JO2681B1 (en) Indole derivatives
MX2010009736A (es) Compuesto heterociclico.
MY152475A (en) Fused ring compounds and use thereof
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
MY154798A (en) Fused cyclic compounds
HK1158192A1 (en) Piperidine gpcr agonists
TW200732341A (en) Chemical compounds
TW200833675A (en) Nicotinamide derivatives
UA96152C2 (en) Dihydropyrazolopyrimidinone derivatives
GB0812642D0 (en) Compounds
TW200745067A (en) Novel compounds
HK1135703A1 (en) Piperidine gpcr agonists
WO2009016462A3 (en) Substituted bicyclolactam compounds
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX2010003440A (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
MX2010003442A (es) Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo.
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
GEP20156222B (en) Pyrazole compound
MX2009013667A (es) Inhibidores triciclicos de hidroxiesteroide deshidrogenasas.
TN2011000294A1 (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
TN2010000450A1 (en) Fused ring compounds and use thereof
TN2010000397A1 (en) Heterocyclic compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration